N-[(3R)-1-(3-bromopropyl)pyrrolidin-3-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine
C19H21BrClN5 — CID 169103488
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[(3R)-1-(3-bromopropyl)pyrrolidin-3-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine
N-[(3R)-1-(3-bromopropyl)pyrrolidin-3-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine (PubChem CID 169103488) has the molecular formula C19H21BrClN5 and a molecular weight of 434.77 g/mol. Its IUPAC name is N-[(3R)-1-(3-bromopropyl)pyrrolidin-3-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine.
Molecular Properties
| Compound Name | N-[(3R)-1-(3-bromopropyl)pyrrolidin-3-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine |
|---|---|
| PubChem CID | 169103488 |
| Molecular Formula | C19H21BrClN5 |
| Molecular Weight | 434.77 g/mol |
| Exact Mass | 433.07 |
| IUPAC Name | N-[(3R)-1-(3-bromopropyl)pyrrolidin-3-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine |
| SMILES | Clc1cnc(N[C@@H]2CCN(CCCBr)C2)nc1-c1c[nH]c2ccccc12 |
| InChI | InChI=1S/C19H21BrClN5/c20-7-3-8-26-9-6-13(12-26)24-19-23-11-16(21)18(25-19)15-10-22-17-5-2-1-4-14(15)17/h1-2,4-5,10-11,13,22H,3,6-9,12H2,(H,23,24,25)/t13-/m1/s1 |
| InChIKey | OBTJSJKTEMNRHZ-CYBMUJFWSA-N |
| XLogP | 4.55 |
| TPSA | 56.84 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 26 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 434.77 |
| LogP ≤ 5 | 4.55 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'alkyl_halide', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 169103488 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.